Demeetra AgBio, Inc. (hereafter "Demeetra") today announced that Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho") has renewed its research license agreement for the piggyBac® transposase technology, a widely used platform for genetic engineering in research applications.LEXINGTON, Ky., Feb. 19, 2026 /PRNewswire-PRWeb/ -- Under the renewed agreement, Taiho will continue to leverage the piggyBac technology for its internal research activities. The license has been granted directly by Demeetra, which acqui ...

Core Insights - Taiho Pharmaceutical Co., Ltd. has exercised its option to develop and commercialize casdatifan, a small molecule HIF-2 inhibitor, in Japan and certain other Asian territories, excluding mainland China [1] Group 1 - The option exercise is based on a 2017 agreement between Taiho and Arcus Biosciences [1]